

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:

Thyrocare Technologies Limited

1. Type of Issue (IPO/FPO)

IPO

2. Issue Size (Rs. Cr)

479.21

3. Grade of issue along with name of the rating agency

Name

NA

Grade

NA

4. Subscription Level (Number of times)

73.77 times (excluding Anchor Investors) (After considering cheque returns, withdrawals, technical/multiple rejection cases).

* Source: Minutes of Basis of Allotment dated May 05, 2016.

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue*	10%
(ii) at the end of the 1st Quarter immediately after the listing of the issue"	14.83%
(iii) at the end of 1st FY (March 31, 2017)"	16.58%
(iv) at the end of 2nd FY (March 31, 2018) "	29.05%
(v) at the end of 3rd FY (March 31, 2019)"	25.41%

(") Source –Shareholding pattern uploaded on the website of NSE representing holding of "Institutions" category.

(* Includes Anchor Investor Portion

6. Financials of the issuer (as per the annual financial standalone results submitted to stock exchanges)

Standalone

(Rs in Crores)

Parameters	1st FY (March 31, 2017)^	2nd FY (March 31, 2018)**	3rd FY (March 31, 2019)*
Income from operations	300.06	331.79	370.28
Net Profit for the period	74.85	96.04	95.23
Paid-up equity share capital	53.72	53.72	52.80
Reserves excluding revaluation reserves	366.71	400.15	402.98

Consolidated

Parameters	1st FY (March 31, 2017)^	2nd FY (March 31, 2018)**	3rd FY (March 31, 2019)*
Income from operations	306.81	356.32	402.91
Net Profit for the period	109.42	93.28	85.14
Paid-up equity share capital	53.72	53.72	52.80
Reserves excluding revaluation reserves	355.06	389.56	382.33

^Annual Report as uploaded on the website of Stock Exchanges for the year ended March 31, 2017

** Results as uploaded on the website of Stock Exchanges for the year ended March 31, 2018

* Results as uploaded on the website of Stock Exchanges for the year ended March 31, 2019

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2017)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2018)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2019)*	Frequently Traded

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2017)	-	-
(ii) at the end of 2nd FY (March 31, 2018)^	- Dr Indumati Gopinathan	Appointed as a Non Executive Director in place of Mr Sohil Chand, the retiring director on August 12, 2017.
(iii) at the end of 3rd FY (March 31, 2019)*	-	-

**However, please note that till July 15, 2019 of the current fiscal year, there has been no changes for FY 2019*

^ Stock Exchange filings.

9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document*:** NA
- (ii) **Actual implementation*:** NA
- (iii) **Reasons for delay in implementation, if any*:** NA

**Not applicable, as the Offer was only an Offer for Sale by Selling Shareholders.*

10. Status of utilization of issue proceeds

- (i) **As disclosed in the offer document*:** NA
- (ii) **Actual utilization*:** NA
- (iii) **Reasons for deviation, if any*:** NA

**Not applicable, as the Offer was only an Offer for Sale by Selling Shareholders.*

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12. Pricing Data

Issue Price (Rs.): 446
Designated Stock Exchange: NSE Limited
Listing Date: May 9, 2016

Price parameters	At close of listing day (i.e. May 9, 2016)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue (March 31, 2017)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	618.80	610.35	546.65	717.8	744.7	523.2
Nifty	7,866.05	8266.45	8711.35	9173.75	9218.4	7715.8
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2018)			As at the end of 3rd FY after the listing of the issue (March 31, 2019)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	596.85	761.15	577.7	533.9	711	485
Nifty	10113.7	11130.4	9103.5	11623.9	11760.2	10004.55
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: National Stock Exchange Limited

13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio		As disclosed in the offer document*	At the end of 1st FY (March 31, 2017)	At the end of 2nd FY (March 31, 2018) ⁽³⁾	At the end of 3rd FY (March 31, 2019) ⁽²⁾
EPS	Issuer:	--	--	--	--
	Standalone (Basic)	8.59 [^]	13.93	17.91	17.84
	Standalone (Diluted)	8.59 [^]	13.91	17.85	17.8
	Consolidated (Basic)	7.89 [^]	13.21	17.39	15.95
	Consolidated (Diluted)	7.88 [^]	13.19	17.34	15.91
	Peer Group ^{^^} :		--	--	--
	Dr. Lal Pathlabs Limited (Basic)	16.53	18.62	20.85	23.74
	Dr. Lal Pathlabs Limited (Diluted)	11.48	18.55	20.82	23.69
	Industry Avg:	--	18.62	20.85	23.74
P/E	Issuer:	--	--	--	--
	Standalone (Basic)	45.56	51.53	33.53	29.93
	Standalone (Diluted)	45.56	51.60	33.64	33.74
	Consolidated (Basic)	49.67	54.34	34.53	33.47
	Consolidated (Diluted)	49.67	54.42	34.63	33.56
	Peer Group:	--	--	--	--
	Dr. Lal Pathlabs Limited (based on basic EPS)	60.60	51.96	42.03	43.99
	Dr. Lal Pathlabs Limited (based on diluted EPS)	87.26	52.16	42.09	44.08
	Industry Composite:	60.60	51.96	42.03	43.99

RoNW (%)	Issuer:	--	--	--	--
	Standalone	11.60 [^]	17.80	21.16	20.89
	Consolidated	10.89 [^]	17.44	21.04	19.57
	Peer Group:	--	--	--	--
	Dr. Lal Pathlabs Limited	27.85	23.52	21.72	20.99
	Industry Composite:	27.85	23.52	21.72	20.99
NAV	Issuer:	--	--	--	--
	Standalone	69.93 [^]	78.29	84.52	86.32
	Consolidated	68.39 [^]	75.75	82.55	82.41
	Peer Group ⁽²⁾ :	--	--	--	--
	Dr. Lal Pathlabs Limited	57.56	79.43	94.97	111.74
	Industry Avg:	57.56	79.43	94.97	111.74

Notes:

(1) Prospectus dated May 3, 2016

(2) Results as uploaded on the website of the Stock Exchanges for the year ended March 31, 2019

[^] Figures for Nine months ended December 31, 2015 and are not annualized

^{^^} Ratios of Dr Lal Pathlabs are computed on consolidated financials mentioned in Annual Report 2016-17.

^{^^^} Ratios of Dr Lal Pathlabs are computed on consolidated financials as per results uploaded on the website of the Stock Exchanges for the year ended March 31, 2018

(3) Results as uploaded on the website of the Stock Exchanges for the year ended March 31, 2018

14. Any other material information

Particulars	Date
The Board decided to acquire the trademark "Whaters" from Dr A. Velumani, Chairman & Managing Director, its registered owner for a token consideration of Re 1/- (Rupee one only) as Dr A. Velumani chose to assign the trademark "Nueclear" from Dr A. Velumani, for a token consideration of Re 1/- only instead of Re 1 Crore approved by NHL Board last year. Dr A Velumani has also decided to waive the royalty payable to him by both the companies for use of the trademark during the year 2016-17.	24-Mar-2017
Thyrocare Technologies Limited has informed the Exchange that Mr. Sohil Chand, nominee director of Norwest Venture Partners-VII-A, Mauritius (NVP), who is retiring at the ensuing annual general meeting of the Company scheduled to be held on Saturday, August 12, 2017, has expressed his intention not to seek reappointment following a policy	05-Aug-2017

decision of NVP and we have received a notice, under Section 160 of the Companies Act 2013, from Sumathi Infra Project LLP, Folio No. IN3004841 2038566, a member holding 15,76,415 equity shares constituting 2.93% of the paid up capital of the Company stating that they propose to move a resolution in the said AGM for appointment of Dr. Indumati Gopinathan as a director in the place of Mr.Sohil Chand.	
Our Company has been holding 5,440 equity shares in Thyrocare International Holding Co, (TIHC) Mauritius, representing 9.09% of the total paid-up capital of the said company, which is not yielding any return. Therefore, the Board of Directors of our company, at their meeting held today, based on the recommendation of the Audit Committee, approved a proposal to sell the entire 5,440 equity shares at the cost price, to one of the relatives of the Promoters, since the other shareholders of THIC declined to acquire the said shares which were first offered to them.	27-Aug-2017
The Board has decided to defer a decision on payment of interim dividend pending assessment of requirement of funds to meet the capex requirements of the wholly-owned subsidiary, Nuclear Healthcare Limited, since the Company has already decided to give them loan to help them acquire costly equipments like Cyclotron, PET-CT Scan machines, etc for setting up additional scanning centres.	09-Dec-2017
The Board has also decided to invest upto Rs 20 Crores in Equinox Labs Private Limited, Navi Mumbai, Rs 10 crore in cash and by divestment of its Water Testing Business to them for a value of Rs 10 crores, on a slump sale basis.	09-Dec-2017
Announcement of launch of Focus TB, the brand for Tuberculosis Testing Services at an affordable cost.	30-Dec-2017
Board Meeting to consider Buyback of Equity Shares	28-Jul-2018
Public Announcement of Buyback of Equity Shares through Open Market Mechanism	11-Sep-2018
Post Buyback Public Announcement dated October 16, 2018 published on October 17, 2019	19-Oct-2018
Board Meeting to approve issue and allotment of new equity shares to employees who exercised the stock options granted to them in 2015	03-Nov-2018
Commencement of operation on tender awarded by Municipal Corporation of Greater Mumbai for availing laboratory investigative services "Aapli Chikitsa"	21-May-2019

Source: Stock exchange filings

All the above information has been updated till July 15, 2019 unless indicated otherwise